+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 7 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating a drug called sigvotatug vedotin SGN-B6A alone and in combination with pembrolizumab, with or without chemotherapy, to assess its safety and effects in people with advanced solid tumors. This Phase 1 study aims to determine the side effects and whether sigvotatug vedotin works to treat various solid tumors including lung, head and neck, breast, esophageal, skin, pancreatic, bladder, cervical, gastric, and ovarian cancers. The study is divided into four parts to explore dosage, safety, and combination treatments. Participants may receive sigvotatug vedotin alone or combined with pembrolizumab, sometimes alongside chemotherapy drugs carboplatin or cisplatin, depending on the study part. Part A focuses on finding the right dose of sigvotatug vedotin. Part B uses this dose to further test safety and effectiveness. Parts C and D study the drug combined with pembrolizumab and possibly chemotherapy in different tumor types and treatment settings, including people who have not previously received treatment. Treatments are given intravenously, with pembrolizumab administered every 3 or 6 weeks and chemotherapy every 3 weeks. During the study, participants undergo tumor biopsies, clinical evaluations, and monitoring for side effects, including blood tests and safety assessments. Researchers track adverse events, lab abnormalities, and dose-limiting toxicities up to 30-37 days after treatment, with some follow-up extending up to 3 years. They also measure tumor response using standard criteria and monitor survival and drug levels in the body. Participants will have regular visits for treatment and assessments throughout the study duration, which may last several years.

Age: 18Years +All GendersPhase 1
158 locations
P

Actively Recruiting

Researchers are evaluating the investigational drug PF-06821497 mevrometostat combined with enzalutamide compared to enzalutamide alone in men with metastatic castration-resistant prostate cancer mCRPC who have not previously received certain systemic treatments. This global, multicenter, randomized Phase 3 study focuses on participants who have mCRPC but have only received androgen deprivation therapy or first-generation anti-androgen agents, excluding prior treatment with androgen receptor signaling inhibitors such as enzalutamide or abiraterone. Participants are randomly assigned to one of two groups one receiving PF-06821497 twice daily plus enzalutamide once daily, and the other receiving a placebo twice daily plus enzalutamide once daily. The study includes several phases screening, randomization, treatment, safety follow-up, and long-term follow-up. Treatment is continuous oral dosing during the treatment phase. Throughout the study, participants will undergo regular assessments including scans, laboratory tests, and patient-reported questionnaires to measure outcomes such as radiographic progression-free survival, overall survival, pain progression, prostate specific antigen levels, and quality of life. Safety is monitored continuously, and follow-up can last up to approximately five years after randomization to evaluate long-term effects and treatment impact.

Age: 18Years +MALEPhase 3
231 locations
A

Actively Recruiting

Researchers are studying a new medicine called PF-08634404 to see how well it works in adults with metastatic colorectal cancer, which is cancer that has spread to other parts of the body. The study compares PF-08634404 combined with approved chemotherapy to an approved medicine called Bevacizumab combined with chemotherapy. The goal is to understand if the new medicine can improve outcomes for people whose cancer has spread or returned after previous treatments. Participants are randomly assigned to one of two treatment groups. One group receives PF-08634404 with chemotherapy, and the other group receives Bevacizumab with chemotherapy. All medicines are given through intravenous IV infusions at a clinical site. Treatment is given in cycles, and participants may continue treatment as long as it is helping and side effects are manageable. After treatment ends, participants return for a final visit around 30 to 37 days later. During the study, participants have regular visits for treatment, health checks, and tests. Follow-up continues every 12 weeks through phone, in-person visits, or health record reviews to monitor health status and any new treatments. Researchers will measure outcomes such as progression-free survival, overall survival, response rates, side effects, quality of life, and drug levels. The study is expected to last about 33 months per participant.

Age: 18Years +All GendersPhase 3
372 locations
T

Actively Recruiting

Researchers are studying the use of FDA-approved targeted therapies for patients with advanced cancer whose tumors have specific genomic changes that may respond to these drugs. This non-randomized Phase 2 trial aims to understand the safety and effects of these targeted anticancer treatments in real-world clinical practice. The study catalogs molecular profiling tests used by doctors and helps develop ideas for further clinical trials. Participants receive one of several targeted drug treatments based on their tumors genetic profile. These include drugs such as sunitinib, trastuzumab with pertuzumab, vemurafenib with cobimetinib, olaparib, nivolumab with ipilimumab, abemaciclib, talazoparib, atezolizumab with talazoparib, tucatinib with trastuzumab, futibatinib, dabrafenib with trametinib, or fam-trastuzumab deruxtecan-nxki. Dosage, frequency, and duration follow approved labeling. Each drug is matched to specific genomic variants identified in the tumor. Participants must be at least 12 years old and have advanced cancer that is no longer benefiting from standard treatment or for which no approved therapy is available. They undergo genomic testing to identify actionable tumor variants and receive treatment accordingly. Researchers assess tumor response at 16 weeks and monitor overall survival for up to 3 years. Safety and treatment effects are observed throughout the study, which lasts until 2028, with results shared publicly as they become available.

Age: 12Years +All GendersPhase 2
181 locations
S

Actively Recruiting

Researchers are evaluating dosing strategies of CDK46 inhibitors in patients aged 60 and older with hormone receptor positive, HER2 negative metastatic breast cancer. The study compares the standard full-dose approach with a titrated dosing method that starts at a lower dose and increases as tolerated. The goal is to help more older patients tolerate side effects and stay on treatment longer to gain the most benefit from these drugs. Participants will choose either palbociclib or ribociclib combined with endocrine therapy, including aromatase inhibitors or fulvestrant. They will be randomly assigned to either the indicated dosing arm, starting at the full approved dose, or the titrated dosing arm, starting at a lower dose and escalating if well tolerated. The treatment cycles follow a 28-day schedule, with doses given orally on days 1-21. During the study, participants will be monitored for time to treatment discontinuation, toxicities, quality of life, dose adjustments, and healthcare utilization for up to 48 months. Patient-reported outcomes will be collected to understand tolerance better. Telehealth visits and remote consenting are allowed per institutional guidelines, supporting patient convenience throughout the trial.

Age: 60Years +All GendersPhase 3
92 locations
R

Actively Recruiting

Researchers are evaluating whether combining the investigational drug mevrometostat PF-06821497 with enzalutamide works better than enzalutamide alone in men with metastatic castration-sensitive prostate cancer mCSPC who have not received androgen receptor pathway inhibitors or chemotherapy for mCSPC. This Phase 3, global, multicenter, randomized, double-blind, placebo-controlled study focuses on participants with prior limited androgen-deprivation therapy and no disease progression or rising PSA before treatment starts. Participants are randomly assigned to one of two groups one receives mevrometostat 875 mg twice daily plus enzalutamide 160 mg once daily, and the other receives a placebo plus enzalutamide at the same dose. The study includes a screening phase, treatment phase, safety follow-up, and long-term follow-up. Treatment is oral and taken continuously during the trial. During the study, participants undergo various assessments including imaging scans to track disease progression, laboratory tests, and patient-reported questionnaires on pain, quality of life, and fatigue. Researchers will monitor radiographic progression-free survival for up to about 4 years and overall survival for up to about 9 years. Safety and pharmacokinetics of mevrometostat combined with enzalutamide are also evaluated. The total duration includes screening, treatment, safety monitoring, and extended follow-up phases.

Age: 18Years +MALEPhase 3
319 locations
C

Actively Recruiting

Researchers are evaluating the cancer vaccine OSE2101 compared to the chemotherapy drug docetaxel in patients with metastatic non-small cell lung cancer NSCLC who have developed resistance to immune checkpoint inhibitors. This phase 3, randomized, open-label study focuses on HLA-A2 positive patients with either squamous or non-squamous NSCLC who are not candidates for surgery or radiation and lack certain genetic alterations that make them eligible for targeted therapies. Participants will be randomly assigned in a 21 ratio to receive either OSE2101 or docetaxel. OSE2101 is given as a subcutaneous injection every three weeks for six cycles, then every eight weeks for the first year, and finally every twelve weeks until the end of the second year. Docetaxel is administered as an intravenous infusion every three weeks. The study also uses companion diagnostic devices to confirm HLA-A2 status. Throughout the study, participants will have regular visits for treatment and monitoring. Researchers will measure overall survival from randomization until death, with an average follow-up of three years. The trial aims to assess the safety and effectiveness of OSE2101 compared to docetaxel in this patient group, with ongoing monitoring until study completion in late 2028.

Age: 18Years +All GendersPhase 3
207 locations